Provided by Tiger Trade Technology Pte. Ltd.

Denali Therapeutics Inc.

24.92
-0.0300-0.12%
Post-market: 24.920.00000.00%19:30 EDT
Volume:680.99K
Turnover:16.96M
Market Cap:3.98B
PE:-8.79
High:25.37
Open:25.25
Low:24.60
Close:24.95
52wk High:27.30
52wk Low:12.58
Shares:159.85M
Float Shares:151.07M
Volume Ratio:0.67
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8353
EPS(LYR):-2.9700
ROE:-54.93%
ROA:-29.15%
PB:4.77
PE(LYR):-8.39

Loading ...

Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report

Simply Wall St.
·
Aug 18

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 07

Earnings Flash (DNLI) Denali Therapeutics Posts Q2 Loss of $0.68, vs. FactSet Est of $0.51 Loss

MT Newswires Live
·
Aug 07

Denali Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Denali Q2 FY26 Net Loss Widens to $127.6 Million; Revenue Turns to $3.6 Million

Reuters
·
Aug 07

Denali Therapeutics Q2 Operating Expenses USD 134.145 Million

Reuters
·
Aug 07

Denali Therapeutics - Projects Q3 2026 Avlayah Net Product Revenue of $10 Mln-$12 Mln

THOMSON REUTERS
·
Aug 07

Denali Therapeutics Q2 Basic EPS USD -0.68

THOMSON REUTERS
·
Aug 07

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

THOMSON REUTERS
·
Aug 07

Denali Therapeutics treatment of frontotemporal dementia granted orphan status

TIPRANKS
·
Aug 03

Earning Preview: Denali Therapeutics Inc. Q2 revenue is expected to increase by 125.86%, institutional views are mostly positive

Earnings Agent
·
Jul 31

Denali Therapeutics Sells Priority Review Voucher for $195 Million Gross Proceeds

Reuters
·
Jul 28

Denali Therapeutics Schedules Quarterly Results Release and Conference Call

Reuters
·
Jul 28

Denali Therapeutics (DNLI) Stock May Trade At A 12% Premium Following AAIC 2026 Plenary News

Simply Wall St.
·
Jul 23

Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC)

TIPRANKS
·
Jul 15

Denali Therapeutics falls -12.4%

TIPRANKS
·
Jul 14

Biogen's Alzheimer's Drug Lowers Toxic Protein, but Results were Mixed

Reuters
·
Jul 14

Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)

TIPRANKS
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Krystal Biotech (KRYS) and Denali Therapeutics (DNLI)

TIPRANKS
·
Jul 13

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's?

Dow Jones
·
Jul 13